Bristol Myers Squibb clarifies Revlimid royalties, shares under legal watch

Bristol Myers Squibb has responded to the US Federal Trade Commission over patent and royalty questions around the cancer drug Revlimid. The stock remains in focus as investors weigh the legal backdrop and pipeline prospects.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-28, 13:32.

Bristol Myers Squibb (US0897961004) has addressed regulatory scrutiny over Revlimid royalties in a detailed response to the US Federal Trade Commission. The New York Stock Exchange-listed pharma group outlined its view on patent settlements and generic entry, as reported in recent US antitrust filings.

FTC focus on Revlimid royalties

The Federal Trade Commission has been examining whether legacy Celgene patent agreements around the cancer therapy Revlimid may have unduly delayed generic competition or maintained elevated royalty streams for Bristol Myers Squibb, according to case documents filed in Washington. FTC case materials on Celgene and Revlimid patents

Bristol Myers Squibb has argued in its submissions that the settlements and licensing structures complied with prevailing patent law and provided a predictable path to generic launches, pointing to agreed phase-in schedules for rival versions of Revlimid from manufacturers such as Dr. Reddys Laboratories and Natco Pharma. The company maintains that royalty arrangements reflect the economic value created by the underlying intellectual property, backed by years of clinical development and regulatory approvals.

Legal backdrop and NYSE listing context

The legal debate over Revlimid royalties is being watched closely by investors in Bristol Myers Squibb shares on the NYSE, where the group trades alongside sector peers Merck and Pfizer in the large-cap US pharma segment. Market commentators highlight that any adverse ruling could affect future settlement practice in the branded drugs space. Wall Street Journal coverage of drug patent settlements

Analyst notes from major houses such as Goldman Sachs and JPMorgan in recent months have underlined that Bristol Myers Squibb remains diversified across oncology, hematology, cardiovascular and immunology, reducing single-product exposure and supporting a long-term pipeline narrative. These research reports typically reference the Revlimid franchise as part of the acquired Celgene portfolio, but stress that newer therapies and development-stage assets could gradually reshape the revenue mix over the next five years.

Revlimid as a key oncology product

Revlimid is a widely used oral cancer therapy indicated for multiple myeloma and certain forms of lymphoma, with broad adoption in the US and Europe and growing presence in some Asian markets. Bristol Myers Squibb markets the product as part of its hematology-oncology franchise while licensing generics under defined royalty-bearing agreements. Bristol Myers Squibb product sales data for Revlimid

Company filings show that Revlimid has historically been one of the largest contributors to the group's oncology revenues, though management expects its relative share to decline as generics gain traction and as newer agents such as Abecma and Breyanzi ramp up. The legal debate over past royalties does not change the current clinical positioning of Revlimid, which continues to be included in standard treatment regimens based on long-term trial evidence and updated guidelines from specialist bodies.

Where Bristol Myers Squibb shares trade

As of 2026-06-26, 16:00, Bristol Myers Squibb shares closed at 48.30 USD on the New York Stock Exchange, according to the official NYSE price data for the BMY ticker. The company's stock remains part of major US healthcare benchmarks followed by institutional and retail investors.

Bristol Myers Squibb at a glance

• Company: Bristol-Myers Squibb Company
• ISIN: US0897961004
• WKN: 850501
• Ticker: BMY
• Trading venue: NYSE
• Price (as of 2026-06-26, 16:00): 48.30 USD
• Market cap: 98.5 billion USD (as of 2026-06-26)
• Sector / industry: Health Care - Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 2026-07-25

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.